AttendMe Owl Logo
AttendMe
Evidence Evolution
Emergency MedicineEmergency Medicine

How This Evidence Evolved

Sepsis Recognition and Early Treatment

From SIRS to Sepsis-3 and beyond

6.3

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

Sepsis-3 later identified inadequate specificity and sensitivity of SIRS criteria and excessive focus on inflammation in earlier definitions.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Rivers’ 2001 trial randomized 263 emergency-department patients with severe sepsis or septic shock to 6 hours of early goal-directed therapy (EGDT) or standard therapy. In-hospital mortality was 30.5% versus 46.5% (p=0.009). Later multicenter trials compared EGDT with contemporary care: ProCESS enrolled 1,341 patients, ARISE 1,600 and ProMISe 1,260. ProCESS found no improvement in 60-day in-hospital mortality; ARISE and ProMISe found no 90-day mortality benefit. These trials limit generalization of the original protocol effect without establishing that all early treatment is ineffective.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Sepsis-3 (2016) defined sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as a SOFA increase ≥2. In adults with suspected infection outside the ICU, qSOFA (≥2 of RR ≥22, altered mentation, SBP ≤100) identifies higher risk of poor outcomes typical of sepsis. It is a prognostic prompt rather than a stand-alone diagnostic definition.
Now

Current standard of care and ongoing research directions

The 2021 Surviving Sepsis Campaign recommends immediate treatment and resuscitation for sepsis and septic shock. Give antimicrobials immediately, ideally within 1 hour, for possible septic shock or a high likelihood of sepsis. For possible sepsis without shock, rapidly assess infectious and non-infectious causes; if concern persists, give antimicrobials within 3 hours of recognition. For low infection likelihood without shock, antimicrobials may be deferred with close monitoring. For sepsis-induced hypoperfusion or septic shock, the guideline weakly suggests at least 30 mL/kg IV crystalloid within the first 3 hours. It weakly suggests dynamic assessment to guide fluids and decreasing elevated lactate while considering clinical context.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What changed from SIRS to Sepsis-3?+
Sepsis-3 defines sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction can be represented by an increase in SOFA score of 2 points or more. The consensus identified inadequate specificity and sensitivity of SIRS criteria and an excessive focus on inflammation in previous definitions.
What happened to early goal-directed therapy for sepsis?+
Rivers’ trial found lower in-hospital mortality with EGDT in severe sepsis or septic shock. ProCESS, ARISE and ProMISe later found no mortality improvement from EGDT over their comparators. This challenges the incremental benefit of the specific protocol in those settings; it does not test whether delaying treatment is safe or establish how widely protocols were abandoned.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026